Saracatinib (AZD0530)

For research use only.

Catalog No.S1006

217 publications

Saracatinib (AZD0530) Chemical Structure

CAS No. 379231-04-6

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 89 In stock
EUR 68 In stock
EUR 167 In stock
EUR 658 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Saracatinib (AZD0530) has been cited by 217 publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.
Features The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.
Targets
c-Src [2]
(Cell-free assay)
LCK [2]
(Cell-free assay)
c-YES [2]
(Cell-free assay)
EGFR (L861Q) [2]
(Cell-free assay)
Lyn [2]
(Cell-free assay)
2.7 nM <4 nM 4 nM 4 nM 5 nM
In vitro

Saracatinib also potently inhibits other Src tyrosine kinase family members including c-Yes, Fyn, Lyn, Blk, Fgr, and Lck with IC50 from 4-10 nM. Saracatinib sensitively inhibits Src Y530F NIH 3T3 with IC50 of 80 nM. Saracatinib significantly impairs the invasion of HT1080 cells through a 3-dimensional collagen matrix and completely inhibits EGF-induced cell scattering in NBT-II bladder cancer cells. [1] Saracatinib potent inhibits Src activation in DU145 and PC3 cells, which through inhibition of Y419 phosphorylation. Saracatinib inhibits the growth of prostate cancer including PC3, DU145, CWR22Rv1 and LNCaP, while Saracatinib shows low activity in LAPC-4, PZ-HPV7 and RWPE-1 cells. Saracatinib induces cell cycle arrest at G1/S but not caspase 3 cleavages. Saracatinib also significantly inhibits DU145 and PC3 migration in the Boyden chamber. [2] Saracatinib gives a potent and sustained blockage of AKT and enhances the sensitivity to irradiation in A549 and Calu-6 cells. [3] Saracatinib inhibits osteoclast in activity, resorption and formation. Saracatinib also reversibly prevents osteoclast precursor migration. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CTV-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnyTnpKSzVyPUCuNFYyPDNizszN MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
LAMA-84 MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\3cFdKSzVyPUCuNVU6QSEQvF2= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
MEG-01 MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMkO2PFgh|ryP Ml3VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
EM-2 NFjFfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jKU2lEPTB;MD6yOlUh|ryP MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
TE-15 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnH[2VKSzVyPUCuNlc1OTJizszN MkLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
NCI-H1648 NV2wPGl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwMkixNVYh|ryP MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
TE-12 NETwd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjuPHBKSzVyPUCuN|I3QCEQvF2= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
LB996-RCC M2DTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwNESxPVYh|ryP NXnGd2xvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
K-562 MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrxNVJQUUN3ME2wMlQ1QTZ5IN88US=> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
D-336MG MmO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mom0TWM2OD1yLkWwN|A1KM7:TR?= MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NOS-1 NF;GSY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFSx[2JKSzVyPUCuOlA2OjlizszN MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
EW-24 M3e1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofJTWM2OD1yLk[yOlk{KM7:TR?= NIDFWZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
BV-173 NWjTWXBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLG[FZKSzVyPUCuOlUzPDlizszN NUf5TmpYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
NCCIT MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXue3ZIUUN3ME2wMlc{OjF6IN88US=> M3XYflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NCI-H1436 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHDTWM2OD1yLke5NFQ6KM7:TR?= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
BB30-HNC Moj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr3TWM2OD1yLki2NlA{KM7:TR?= NYj1N2Z1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
TE-8 M4TWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwOEeyO|Uh|ryP NXSwNFl7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
A704 NIfhTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[1bZlKSzVyPUCuPFkzOSEQvF2= Mo\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
TK10 NEPVS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfObGw3UUN3ME2wMlkxPjZ7IN88US=> NGTpNpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
KS-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjFO|NzUUN3ME2xMlE6Pzd7IN88US=> NV2zRYNuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
C2BBe1 NFq0b3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLpT4ZKSzVyPUGuNlA2ODdizszN M{PIeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
RXF393 MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfGTWM2OD1zLkK0N|Yh|ryP MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
KGN NGnDSFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIG0fmRKSzVyPUGuNlc3QDdizszN MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NB69 M1[3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHW[nBKSzVyPUGuN|c1QTdizszN NH\ZXFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
TE-11 NFfP[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFwNEO0NVgh|ryP NXnmfZpRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
TE-1 Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXtSHZpUUN3ME2xMlQ1OTB3IN88US=> M1SwTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
ST486 NIe4Wm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XnTGlEPTB;MT60OVg2OiEQvF2= NF\1R2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
HOP-62 M4q4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:1TWM2OD1zLkWwNlQ3KM7:TR?= NFXDRmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
EW-16 M3HDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3GfoxKSzVyPUGuOVUxQDNizszN NYeyT45KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
LB1047-RCC M1;6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTFwNUW0OVMh|ryP NWf4U2xHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
TE-10 NYDrOXpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnP[5ZKSzVyPUGuOlYzPTJizszN M3ztU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
RL95-2 NIfnWHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TINmlEPTB;MT62OlkxOiEQvF2= MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
DOHH-2 NFTtV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PSdGlEPTB;MT63NVc5OiEQvF2= NWrvb3B5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
MFH-ino NYfYe25WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHlPXlXUUN3ME2xMlc4QDdizszN NUfEcVVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
GB-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfFbYhKSzVyPUGuO|k5OzNizszN NFTCfXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
SK-N-DZ NF\xbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHYOpZKSzVyPUGuPFQ3QDhizszN NGfVXYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
OS-RC-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj6TXBKSzVyPUGuPFg2PzRizszN MoX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
SW982 M3\Rc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\zTWM2OD1zLkmyNFk{KM7:TR?= NEDRZ3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
KALS-1 NH6wZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LiUmlEPTB;MT65PFczOiEQvF2= NILOV2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
TGBC24TKB MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHLTWM2OD1{LkC1PVU5KM7:TR?= NWfGOnVCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
GI-1 M3LWPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPPdmY{UUN3ME2yMlE3ODh2IN88US=> MoXPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
SW962 NV;TOohoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi3TWM2OD1{LkG3NVc5KM7:TR?= MkniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
SW872 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjaTWM2OD1{LkG4OVA4KM7:TR?= M3;KeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NCI-H747 NIXJWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3JeZFYUUN3ME2yMlI2PzF2IN88US=> MoKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
MZ1-PC MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJwMkmzOVYh|ryP M4Llb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
MSTO-211H NU\vOI9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLrfGxyUUN3ME2yMlM2PzJ|IN88US=> MmHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
BL-70 NGLHfHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjNWolKSzVyPUKuOFc1OjJizszN M4KzR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
SW954 NGGzeYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjjTWM2OD1{LkW3OFA5KM7:TR?= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
SNB75 Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILabmxKSzVyPUKuOlg2QTRizszN MoLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
IST-SL2 NUfqTXlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vMc2lEPTB;Mj63NlM4QSEQvF2= MoX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
GCIY NVLIUpFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJwOEewNFUh|ryP MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
KU812 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYqz[ZhUUUN3ME2zMlA2Ojl7IN88US=> MkLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
LXF-289 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTNwMUKxNFkh|ryP NF32UFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
ETK-1 MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrPTWM2OD1|LkKwO|Y4KM7:TR?= NHvIVJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
SF126 M3nQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTNwM{GxO|Qh|ryP MnXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
LC-2-ad NFnnem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXztRZNnUUN3ME2zMlU2PyEQvF2= MnrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
KNS-42 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7kS5ZpUUN3ME2zMlY2KM7:TR?= NFjQWVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
OVCAR-4 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInObYlKSzVyPUOuO|M1OzNizszN MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
PF-382 NEHiU2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[4SG9pUUN3ME2zMlg{Pjl6IN88US=> NUTsOGtjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
SH-4 NFy0NIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7aTWM2OD12LkK1NlU6KM7:TR?= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
KM12 M4eybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LuNGlEPTB;ND6zNlQyPiEQvF2= NF\He3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
NB5 Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTlPG0zUUN3ME20MlQyQDZ2IN88US=> NWPid4JwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
KURAMOCHI NYLKUGVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETwTVNKSzVyPUSuOlUzPTZizszN NWLBc25XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
Becker MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\5NndCUUN3ME20MlY3PDF4IN88US=> M4X6XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
MV-4-11 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnhTWM2OD12LkixN|Q1KM7:TR?= NHfid|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
KINGS-1 NVftW3JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;YXmlEPTB;ND64NlM4OyEQvF2= NGO1RVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
LS-123 M{fobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLqcIlKSzVyPUWuOFk3QDRizszN NHHodmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
SF268 NUewOZR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzyTWM2OD13Lk[xNlYzKM7:TR?= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
A388 NUT0fZVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PLSWlEPTB;NT62N|Y3PyEQvF2= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NMC-G1 M4jIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzQbnZKSzVyPU[uNFE5OTFizszN M{HCTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
CGTH-W-1 M2PYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXRdIdKSzVyPU[uNFIxPzVizszN MlH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
ES4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PHUmlEPTB;Nj61N|A4PCEQvF2= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
SR MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jneGlEPTB;Nj61PFgxPyEQvF2= NUPLc|ZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
BB49-HNC MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTZwN{OyNFYh|ryP NXTkcoE3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
KLE M322W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PhPGlEPTB;Nj63PFM4PyEQvF2= Ml;xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
HUTU-80 M4nF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHaTWM2OD14Lkm4OFY3KM7:TR?= NUj1[IdNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
SNU-C2B NI[2NpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS5ZopFUUN3ME23MlgzPzN5IN88US=> M3\LVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
BB65-RCC MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\VZZJzUUN3ME23Mlk1QTB2IN88US=> NXnYTGxpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
QIMR-WIL M{jEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXizO41pUUN3ME24MlQzQDB6IN88US=> NVTEN41YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
GDM-1 MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRThwOUeyPVIh|ryP M4PoNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
LC4-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;LTWM2OD17LkCwPVEyKM7:TR?= M4mxUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
MLMA MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPQSm9KSzVyPUmuNVUxODZizszN MknUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
EoL-1-cell MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXYTWM2OD17LkOwNVkzKM7:TR?= NIDhO409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
BOKU NYTGdll1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLCTWM2OD17Lkm2OFY3KM7:TR?= NVr5eIdzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
EVSA-T MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTvbo5SUUN3ME2xNE43PTZ6IN88US=> NWPLNHlFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
D-283MED MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O1[mlEPTB;MUCuPVE4PiEQvF2= M4T4XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NB1 NYrQcY95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFzLkCyOFIh|ryP M{S4dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
RPMI-8402 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnp[WdoUUN3ME2xNU4yPzhizszN NWjkWY1wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
NCI-H1355 NGWzXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTFzLkG4NFYh|ryP MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NB7 NVzUZWJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTFzLkOyPVch|ryP NFK5S|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
RPMI-6666 M2myWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3yTWM2OD1zMj65OVY4KM7:TR?= MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
697 NFXodVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nLN2lEPTB;MUOuNlcxOSEQvF2= MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
CTB-1 NIPadFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHle4Q4UUN3ME2xN{42QTR6IN88US=> NI\UOFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
VA-ES-BJ NV;rfHBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vkVWlEPTB;MUOuPVI{PCEQvF2= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
BE-13 NHXkNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHXN5hKSzVyPUG0MlM6OTVizszN NVXId4YxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
SKM-1 MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DO[GlEPTB;MUSuOFQ6QSEQvF2= NGDW[G49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
TE-6 NXPZV3pTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe4OFVKSzVyPUG0Mlc2QTFizszN NI\3e5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
LB771-HNC M3fmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfWbppQUUN3ME2xOE44QDl6IN88US=> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
ECC4 M{O4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF5LkCyO|ch|ryP M{fJVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
ES3 MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrOPXZKSzVyPUG3MlQ3PTVizszN M2LVc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
LB647-SCLC NIDYfHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF5LkS5OFkh|ryP MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NB10 MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF6LkWyOVYh|ryP MlnLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
L-540 M1;TWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF6LkixNFkh|ryP Mn[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
NCI-H2126 Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr5PJNKSzVyPUG5MlUyKM7:TR?= MmLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
HH M3Wye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjOd4hKSzVyPUKwMlAxQTlizszN NIGzWnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
MPP-89 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPrPYhOUUN3ME2yN{4zOjh7IN88US=> M2DQcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
IST-MEL1 NH64Sm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfBZWNJUUN3ME2yN{45PjV6IN88US=> NWfyWYhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
KP-N-YS NFPiTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC1OZRKUUN3ME2yN{46OjV3IN88US=> NWnNdFhMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
EC-GI-10 Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ2LkW5PFkh|ryP MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
EKVX NGjhZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfITWM2OD1{Nj6wNlA{KM7:TR?= MmG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
TGBC1TKB MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki0TWM2OD1{Nj60N|Qh|ryP NYDVVlZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
Daudi M2nNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfROZZKSzVyPUK3MlA4PzNizszN NGnGcI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
ALL-PO MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TlbWlEPTB;MkeuNFgyKM7:TR?= MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NB6 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ5LkS4PEDPxE1? MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
ES6 NUfuSVVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K1TmlEPTB;MkeuPVEzOyEQvF2= NUCzOZVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
COLO-320-HSR M3THcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfMeWxVUUN3ME2yPE4xOzd|IN88US=> MkHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
K5 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v6[WlEPTB;MkiuNVI5PyEQvF2= NGPGWFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
ES1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq4co5KSzVyPUK4Mlc4PzNizszN MmqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
LC-1F M4r4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L4fGlEPTB;MkmuO|M1PiEQvF2= M2C5N|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
SCLC-21H NH6wWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;wR2lEPTB;M{CuO|MyPyEQvF2= NHT1cHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
SK-PN-DW MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\n[5lPUUN3ME2zNk42PTl6IN88US=> MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
D-247MG MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLUZmdQUUN3ME2zNk46Pzd|IN88US=> NHTFdFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
TE-5 NHH4OlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4SzbmlEPTB;M{OuNFM3OiEQvF2= MmrqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
MONO-MAC-6 Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTN|LkWwOFgh|ryP NF\ncpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
LB2518-MEL MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorjTWM2OD1|Mz63OlY3KM7:TR?= NIDsOnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
LOXIMVI M3jjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X0cGlEPTB;M{OuO|kzQCEQvF2= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NCI-H209 MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELVRnNKSzVyPUO1MlE1PCEQvF2= NVvUbYRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
A253 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\JWZJSUUN3ME2zOU44PDJ7IN88US=> M3r1SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
HCC1599 M2HSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O2RWlEPTB;M{[uO|A2OyEQvF2= MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
EB-3 M4nKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTN4Lkm1NVgh|ryP M1v4clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
GOTO M1rCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj4[JhmUUN3ME2zO{4{OjJ2IN88US=> NHXGcpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
SW684 NU[2Zot1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonhTWM2OD12MT64OFk2KM7:TR?= NFjzR3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
DEL NXPpNXZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTR{LkC1NlIh|ryP NFz1N5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
HT-144 NHfleWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW5SoxKSzVyPUSyMlE3PzZizszN NF7sRYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
TE-9 M4PDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn1U5hKSzVyPUSzMlQ2QTZizszN NVj2So4xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
KARPAS-45 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jEU2lEPTB;NESuN|kzPSEQvF2= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
HAL-01 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjRcZdKSzVyPUS0MlUxOzRizszN MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
RCC10RGB MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfuWVFCUUN3ME20OE44Ozl{IN88US=> MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
CP67-MEL MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PIc2lEPTB;NEWuOlI1OSEQvF2= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NB17 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTR3Lk[2OFMh|ryP M{L1PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
SK-UT-1 NE\j[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjFS5JKSzVyPUS1Mlk1PjRizszN NV\JNJhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
JiyoyeP-2003 NV3iNYoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PJ[GlEPTB;NE[uNFEyQSEQvF2= MoKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
HCE-4 NUPX[W8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTR4LkW5Olgh|ryP MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NCI-H720 M4HncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\BUGlEPTB;NE[uO|Y5OiEQvF2= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
KARPAS-422 NHXxOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK3dnhQUUN3ME20O{4xQDl3IN88US=> M3fqV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10 M4rSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\XTWM2OD12Nz6xOlIzKM7:TR?= NXv5N|l7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
HCE-T NH21PJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDQTWM2OD12Nz62PFI5KM7:TR?= NHHN[pI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK|5USU6JRWK8M4E,
PSN1 NW\RbXVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LlcmlEPTB;NEeuO|gyOyEQvF2= M1naVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NIH3T3 NUL5XZlDTnWwY4Tpc44h[XO|YYm= Mm\GTY5pcWKrdHnvckBw\iCqdX3hckBkNVO{YzDpckBPUUh|VEOgZ4VtdHNuIFnDOVAhRSByLkCwNlch|ryPLh?= NFz5OlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{C2OFA3Pid-MUewOlQxPjZ:L3G+
HEK293 NVrPR3NDTnWwY4Tpc44h[XO|YYm= NV;KXYNuOSCqch?= MYfJcohq[mm2aX;uJI9nKGi3bXHuJIZ2dGxibHXu[5RpKFCNTWnUNUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJJV{cW6pIFXGV{ApOjR5IITvJFI2QSC{ZYPp[JVmeyliYYOgd5Vje3S{YYTlJIFnfGW{IEGgbJIh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCrbX31co9ie2G7LDDLbUA:KDBwMEO5PEDPxE1w MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl2MUG5N{c,Ojl7NEGxPVM9N2F-
HEK293 MY\GeY5kfGmxbjDhd5NigQ>? M1Tu[|EhcHJ? NVTVfmN6UW6qaXLpeIlwdiCxZjDoeY1idiCodXzsJIxmdme2aDDQT21[XDFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC3c3nu[{BGTlNiKEK0O{B1dyB{NUmgdoV{cWS3ZYOpJIF{KHO3YoP0doF1\SCjZoTldkAyKGi{IHL5JIZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gbY1ufW6xYYPhfUwhUUN3MDC9JFAvPDF6IN88UU4> M2TxNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OUSxNVk{Lz5{OUm0NVE6OzxxYU6=
Rh30 MnvhRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MkDrOFghcHK| NXHV[3FZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSbFMxKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGy3bXnu[ZNk\W62IHHzd4F6NCCLQ{WwJF0hOTBwMTFOwG0v NHnkbIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e4O|A6QSd-MkO3PFcxQTl:L3G+
Huh7 M1jSc2FvfGm4aYLhcEBie3OjeR?= Mm\2Nk42KHWP Mni3OUBl[Xm| MkeyTY5pcWKrdHnvckBw\iC4aYLhcEB{eHKnYXSgbY4hTGWwZ4XlJJZqenW|LXnu[oVkfGWmIHj1cYFvKEi3aEegZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKG:oII\pdoFtKGWwdnXsc5BmKHC{b4TlbY4hf2m2aHnuJJBmemmwdXPs[YFzKHKnZ3nvckBifCB{LkWgeW0h[W[2ZYKgOUBl[Xm|IHL5JIludXWwb3\seY9z\XOlZX7j[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;s M3riR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{[wOlc3Lz5zN{O2NFY4PjxxYU6=
Huh7 NXnnVpJ5SW62aY\pdoFtKGG|c3H5 NIrvVXozNjVidV2= NWTBVYY{PiCmYYnz NGDGO3hKdmirYnn0bY9vKG:oII\pdoFtKHOycnXh[EBqdiCGZX7neYUhfmm{dYOtbY5n\WO2ZXSgbJVu[W5iSIXoO{Bk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[geolz[WxiZX72[YxweGVicILveIVqdiC5aYTobY4heGW{aX71Z4xm[XJicnXnbY9vKGG2IEKuOUB2VSCjZoTldkA3KGSjeYOgZpkhcW2vdX7v[ox2d3Knc3PlcoNmKGG|c3H5JJJmdGG2aY\lJJRwKGOxboTyc4w> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN4ME[3Okc,OTd|NkC2O|Y9N2F-
Vero MmTpRY51cX[rcnHsJIF{e2G7 M13TXVIvPSC3TR?= NYLiNXdZPCCmYYnz M{S5RmlvcGmkaYTpc44hd2ZidnnyZYwhe3C{ZXHkJIlvKESnbnf1[UB3cXK3cz3pcoZm[3SnZDDh[pJq[2GwIHfy[YVvKG2xbnvlfUBX\XKxIHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXNJIFnfGW{IESg[IF6eyCkeTDpcY12dm:obIXvdoV{[2WwY3WgZZN{[XlicnXsZZRqfmVidH:gZ49vfHKxbB?= MlHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd|NkC2O|YoRjF5M{[wOlc3RC:jPh?=
Vero NUOwPI5RSW62aY\pdoFtKGG|c3H5 M4DzZlIvPSC3TR?= NH:1boQ3KGSjeYO= Mn;3TY5pcWKrdHnvckBw\iC4aYLhcEB{eHKnYXSgbY4hTGWwZ4XlJJZqenW|LXnu[oVkfGWmIHHmdolk[W5iZ4Ll[Y4hdW:wa3X5JHZmem9iY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2gZYZ1\XJiNjDkZZl{KGK7IHntcZVvd2[udX;y[ZNk\W6lZTDhd5NigSC{ZXzheIl3\SC2bzDjc451em:u MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN4ME[3Okc,OTd|NkC2O|Y9N2F-
C6/36 MlvDRY51cX[rcnHsJIF{e2G7 NYL5eml2Oi53IIXN M3iwO|Qh\GG7cx?= NVzObI1SUW6qaXLpeIlwdiCxZjD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVOKGGodHXyJFQh\GG7czDifUBqdW23bn;mcJVwemW|Y3XuZ4Uh[XO|YYmgdoVt[XSrdnWgeI8h[2:wdILvcC=> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN4ME[3Okc,OTd|NkC2O|Y9N2F-
C6/36 M1jJXGFvfGm4aYLhcEBie3OjeR?= M1nrSFIvPSC3TR?= NFrrR5c2KGSjeYO= M4jKdWlvcGmkaYTpc44hd2ZidnnyZYwhe3C{ZXHkJIlvKESnbnf1[UB3cXK3cz3pcoZm[3SnZDDhd4lidiC2aXfldkBud3OzdXn0c{BEPi9|NjDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44hd2ZidnnyZYwh\W64ZXzvdIUheHKxdHXpckB4cXSqaX6gdIVzcW63Y3zlZZIhemWpaX;uJIF1KDJwNTD1UUBi\nSncjC1JIRigXNiYomgbY1ufW6xZnz1c5Jme2OnbnPlJIF{e2G7IILlcIF1cX[nIITvJINwdnS{b3y= MmO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd|NkC2O|YoRjF5M{[wOlc3RC:jPh?=
Vero MYLBcpRqfmm{YXygZZN{[Xl? M3i5bFMh\GG7cx?= M1G5TmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGRmdme3ZTD2bZJ2eyCrbn\lZ5Rm\CCrbjDh[pJq[2GwIHfy[YVvKG2xbnvlfUBX\XKxIHPlcIx{KGGmbXnubZN1\XKnZDDh[pRmeiC4aYLhcEBkcGGubHXu[4Uh[W[2ZYKgN{Bl[Xm|IHL5JJZqemGuIIDsZZF2\SCjc4PhfS=> NH;ZZmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{O2NFY4Pid-MUezOlA3PzZ:L3G+
Vero MYTBcpRqfmm{YXygZZN{[Xl? NIDIV|MzNjVidV2= NWjwOVByPSCmYYnz MWXJcohq[mm2aX;uJI9nKH[rcnHsJJNxemWjZDDpckBF\W6pdXWgeolzfXNvaX7m[YN1\WRiYX\ybYNidiCpcnXlckBud26tZYmgWoVzdyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TTDh[pRmeiB3IHThfZMh[nliaX3teY5w\my3b4Lld4NmdmOnIHHzd4F6KHKnbHH0bZZmKHSxIHPvcpRzd2x? NWHoc4hqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezOlA3PzZpPkG3N|YxPjd4PD;hQi=>
Huh7 Moj4RY51cX[rcnHsJIF{e2G7 MWCyMlUhfU1? NEizRXg1KGSjeYO= MnHOTY5pcWKrdHnvckBw\iC4aYLhcEB{eHKnYXSgbY4hTGWwZ4XlJJZqenW|LXnu[oVkfGWmIHj1cYFvKEi3aEegZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKG:oII\pdoFtKGWwdnXsc5BmKHC{b4TlbY4hf2m2aHnuJJBmemmwdXPs[YFzKHKnZ3nvckBifCB{LkWgeW0h[W[2ZYKgOEBl[Xm|IHL5JIludXWwb3\seY9z\XOlZX7j[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;s MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN4ME[3Okc,OTd|NkC2O|Y9N2F-
C6/36 M3rwUWFvfGm4aYLhcEBie3OjeR?= MnXWNk42KHWP MoD0OkBl[Xm| NE\ZflBKdmirYnn0bY9vKG:oII\pdoFtKHOycnXh[EBqdiCGZX7neYUhfmm{dYOtbY5n\WO2ZXSgZZNq[W5idHnn[ZIhdW:|cYXpeI8hSzZxM{[gZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKG:oII\pdoFtKGWwdnXsc5BmKHC{b4TlbY4hf2m2aHnuJJBmemmwdXPs[YFzKHKnZ3nvckBifCB{LkWgeW0h[W[2ZYKgOkBl[Xm|IHL5JIludXWwb3\seY9z\XOlZX7j[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;s NUjmUGFHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezOlA3PzZpPkG3N|YxPjd4PD;hQi=>
HEK293 M{n5OmZ2dmO2aX;uJIF{e2G7 M17JWFAvOSC2bzCxJJVO MmLLNVYhcHK| MW\Jcohq[mm2aX;uJI9nKGOxbHzh[4VvKElvaX7keYNm\CCGRGKyJEh2dmuwb4fuJI9zcWerbjmgdIhwe3Cqb4L5cIF1cW:wIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYSgNE4yKHSxIEGgeW0h[W[2ZYKgNVYhcHK|IHL5JHdme3Sncn6gZoxwfHSrbne= M3vNWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUmxN|Y6Lz5{NkG5NVM3QTxxYU6=
A673 M2HvS5FJXFNiYYPzZZk> MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? M3PLVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY NV7oV3lReUiWUzDhd5NigQ>? NHn0eGxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?= M121d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 NH:2RoVyUFSVIHHzd4F6 MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD MVfxTHRUKGG|c3H5 M{PmdJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH M2jnVZFJXFNiYYPzZZk> MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= Mmm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 NVzSZoVneUiWUzDhd5NigQ>? NHPWVFFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz MljmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 MojwdWhVWyCjc4PhfS=> M1PUNJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz M2PZfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC NIXTWI9yUFSVIHHzd4F6 M2e5SJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 NYfYdXg6eUiWUzDhd5NigQ>? M2PnSZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?= NH7Y[VU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
HEK293 NVXkbFltTnWwY4Tpc44h[XO|YYm= NXXCOmJVOC5zIITvJFEhfU1? M3HJSlE3KGi{cx?= MnOxTY5pcWKrdHnvckBw\iClb3zsZYdmdiCLLXnu[JVk\WRiRFTSNkBKPjN6RjDteZRidnRiKIXub45wf25ib4Lp[4lvMSCyaH;zdIhwenmuYYTpc44h\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{BifCByLkGgeI8hOSC3TTDh[pRmeiBzNjDodpMh[nliV3XzeIVzdiCkbH;0eIlv\w>? MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF7MUO2PUc,OjZzOUGzOlk9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pY576-FAK / pY861-FAK / FAK; 

PubMed: 20551056     


(A) HCT116 (left) and WiDr (right) cells were exposed to the indicated concentrations of saracatinib for 24 hours and the effect on total FAK or FAK phosphorylation on tyrosine 576 or 861 was assessed by western blotting. Result is representative of three independent experiments.

pY418 Src / Src / pY410 CAS / CAS / Py421 Cortactin / Cortactin; 

PubMed: 20505783     


Saracatinib inhibits Src activity and downstream Src substrate phosphorylation in HNSCC cell lines. HN31, UMSCC1 and 1483 cells were treated with DMSO vehicle or saracatinib (0.01–1 μM) for 24 h. Cells were lysed and total protein amounts were analyzed by Western blotting with total or phosphorylation site-specific antibodies for Src and the indicated substrates. Blots shown are representative of at least four independent experiments, with band intensities for each substrate quantified relative to the untreated (0 μM) condition for each cell line.

p-Akt / p-mTOR / Akt / mTOR / p-S6 / S6 / p-AMPKα / AMPKα; 

PubMed: 20811583     


PC3 cells were treated with 10 μM PP2 (left panel)/1 μM saracatinib (right panel) for 0.5, 1, 2, 4, 8, and 24 h. Cell lysates were analyzed by immunoblotting with antibodies as indicated. Controls were treated with vehicle alone. β-actin was detected as loading control.

20551056 20505783 20811583
Growth inhibition assay
Cell number; 

PubMed: 24349321     


LNCaP 104-S, 104-R1, 104-R2, PC-3, and DU-145 cells were treated with increasing concentrations of  Saracatinib for 72 hrs. Relative cell number of LNCaP cells was determined by Hoechst dye 33258-based 96-well proliferation assay. Cell numbers were normalized to control (dimethylsulfoxide) of each cell line. Triple asterisks (***) represent statistically significant difference p <0.001 between the treated group and the control group.

24349321
In vivo

Saracatinib shows great tumor growth inhibition in Src3T3 allografts and a moderate growth delay in Calu-6, MDA-MB-231, AsPc-1 and BT474C xenografts. [1] Saracatinib shows great antitumor activity in orthotopic DU145 xenograft mice at a dose of 25mg/kg (orally administered, daily). [2]

Protocol

Kinase Assay:

[1]

- Collapse

Kinase Assay:

IC50 of tyrosine kinase activity is measured by an enzyme-linked immunosorbent assay (ELISA) with recombinant catalytic domains of a panel of receptor and non-receptor tyrosine kinases (in some cases only part of the catalytic domain is used). Saracatinib dose ranges from 0.001-10 mM. Specificity assays against a panel of serine/threonine kinases are performed using a filter capture assay with 32P. Briefly, multidrop 384 plates containing 0.5 μL Saracatinib or controls (DMSO) alone or pH 3.0 buffer controls) are incubated with 15 μL of enzyme plus peptide/protein substrate for 5 min before the reaction is initiated by the addition of 10 μL of 20 mM Mg-ATP. For all enzymes the final concentration is approximated to the Michaelis constant (Km). Assays are carried out for 30min at room temperature before termination by the addition of 5 μL orthophosphoric acid. After mixing, the well contents are harvested onto a P81 Unifilter plate, using orthophosphoric acid as the wash buffer. Then IC50 is calculated.
Cell Research:

[1]

- Collapse
  • Cell lines: PC3, DU145, CWR22Rv1, LNCaP, LAPC-4, PZ-HPV7 and RWPE-1 cells
  • Concentrations: 62.5 nM - 16 mM
  • Incubation Time: 1, 3 and 5 days
  • Method:

    Cells are seeded at a density of 2× 103 in 96-well plates and incubated overnight. Then Saracatinib (62.5 nM-16 mM) is added to the cells. After 1, 3 and 5 days, culture medium is removed followed by addition of 0.2 mL DMSO per well and continuous shaking of plates at 200 rotations per minute for 15min. Then IC50 is measured by MTT metho


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: CB17 mice are implanted with DU145 cells.
  • Dosages: 25 mg/kg
  • Administration: Orally administered daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (64.57 mM)
Ethanol 31 mg/mL (57.19 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 542.03
Formula

C27H32ClN5O5

CAS No. 379231-04-6
Storage powder
in solvent
Synonyms N/A
Smiles CN1CCN(CC1)CCOC2=CC3=C(C(=C2)OC4CCOCC4)C(=NC=N3)NC5=C(C=CC6=C5OCO6)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04598919 Recruiting Drug: Saracatinab|Drug: Placebo Idiopathic Pulmonary Fibrosis (IPF) National Jewish Health|Yale University|Icahn School of Medicine at Mount Sinai|AstraZeneca|National Center for Advancing Translational Science (NCATS) November 12 2020 Phase 1|Phase 2
NCT04307953 Recruiting Drug: AZD0530 Difumarate|Drug: Matching placebo Fibrodysplasia Ossificans Progressiva VU University Medical Center|Royal National Orthopaedic Hospital NHS Trust|Klinikum Garmisch-Patenkirchen|University of Oxford|Brigham and Women''s Hospital|AstraZeneca|Innovative Medicines Initiative August 5 2020 Phase 2
NCT02085603 Completed Drug: Saracatinib|Drug: Placebo Cancer Sheffield Teaching Hospitals NHS Foundation Trust|AstraZeneca March 2014 Phase 2
NCT01864655 Completed Drug: saracatinib|Drug: Placebo Alzheimer''s Disease Stephen M. Strittmatter|Yale University July 2013 Phase 1
NCT01000896 Withdrawn Drug: AZD0530|Drug: Carboplatin|Drug: paclitaxel Cancer|Non Small Cell Lung Cancer|Epithelial Ovarian Cancer AstraZeneca January 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the half-life of Saracatinib?

  • Answer:

    Based on the following paper, the half-life of Saracatinib in vivo is around 40hours and it reaches its peak lever around 2-4 hours after dosing: http://clincancerres.aacrjournals.org/content/16/19/4876.long

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Saracatinib (AZD0530) | Saracatinib (AZD0530) supplier | purchase Saracatinib (AZD0530) | Saracatinib (AZD0530) cost | Saracatinib (AZD0530) manufacturer | order Saracatinib (AZD0530) | Saracatinib (AZD0530) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID